Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.

[1]  K. Anstrom,et al.  Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial , 2019, JAMA.

[2]  M. Hadamitzky,et al.  Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial , 2018, European heart journal.

[3]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[4]  J. Messenger,et al.  Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.

[5]  J. Messenger,et al.  Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.

[6]  K. Anstrom,et al.  Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and , 2016, Circulation. Cardiovascular interventions.

[7]  Sandy Jeong Rhie,et al.  Factors affecting medication adherence in elderly people , 2016, Patient preference and adherence.

[8]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[9]  D. Forman,et al.  Geriatric Cardiology: An Emerging Discipline. , 2016, The Canadian journal of cardiology.

[10]  N. Tang,et al.  Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: comment , 2016, Journal of thrombosis and haemostasis : JTH.

[11]  Harlan M Krumholz,et al.  2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa , 2016, Journal of the American College of Cardiology.

[12]  H. Suryapranata,et al.  Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor , 2016, Journal of thrombosis and haemostasis : JTH.

[13]  F. Eberli,et al.  Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.

[14]  M. Tinetti,et al.  What to Expect From the Evolving Field of Geriatric Cardiology. , 2015, Journal of the American College of Cardiology.

[15]  Walter Desmet,et al.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.

[16]  Jeroen J. Bax,et al.  The universal definition of myocardial infarction , 2015, Oxford Medicine Online.

[17]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[18]  Antonio Colombo,et al.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.

[19]  V. Fuster,et al.  A polypill strategy to improve adherence: results from the FOCUS project. , 2014, Journal of the American College of Cardiology.

[20]  S. Pocock,et al.  to improve adherence : results from FOCUS ( Fixed-dose Combination Drug for Secondary Cardiovascular Prevention ) Project , 2014 .

[21]  H. Yokoi.  [Antiplatelet therapy after drug-eluting stent implantation]. , 2014, Nihon rinsho. Japanese journal of clinical medicine.

[22]  Daniel E Forman,et al.  Frailty assessment in the cardiovascular care of older adults. , 2014, Journal of the American College of Cardiology.

[23]  Deepak L. Bhatt,et al.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.

[24]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[25]  M. Jaguszewski,et al.  Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications. , 2013, Cardiology journal.

[26]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[27]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[28]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[29]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[30]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[31]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[32]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[33]  Beat Kleiner,et al.  Graphical Methods for Data Analysis , 1983 .

[34]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[35]  G. Stone,et al.  Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta‐analysis , 2018, American heart journal.